EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Inflammatory cytokines and immune signalling in heart failure: mechanisms, models, and emerging therapies

Guiomar Mendieta iD, Gianluigi Pironti iD, Jasper Tromp iD, Lars H Lund

Cardiovascular Research · 10.10.2026 · 122 (14) · 1901-1921

DOI: 10.1093/cvr/cvag172 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 18.08.2026. Verfasst von Guiomar Mendieta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), CIBERCV, Universitat Autònoma de Barcelon…. Hauptthemen laut MEDLINE: Heart Failure, Cytokines, Inflammation Mediators, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 301 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation plays a central role in the pathophysiology of heart failure (HF), and contributes to disease progression, morbidity, and mortality. However, the relationships between inflammatory cytokines and different HF subtypes are complex, heterogeneous, and bidirectional. In this review, we examine inflammatory pathways, biomarker profiles, and comorbidities in HF with reduced, mildly reduced, and preserved ejection fraction and summarize evidence on the use of high-sensitivity C-reactive protein as a biomarker for systemic inflammation in HF. We provide insights into emerging methodologies for biomarker discovery in HF and discuss the use of animal models to elucidate underlying mechanisms and test potential treatment strategies. Finally, we provide an overview of the therapeutic landscape, touching on past challenges and future opportunities for the development of targeted anti-inflammatory therapies in HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureCytokinesInflammation MediatorsAnti-Inflammatory AgentsInflammationHumansAnimalsSignal TransductionBiomarkersDisease Models, AnimalC-Reactive ProteinMolecular Targeted Therapy

Stichwörter der Autor:innen

Animal modelsComorbiditiesHeart failureHigh-sensitivity C-reactive proteinIL-6

Substanzen

CytokinesInflammation MediatorsAnti-Inflammatory AgentsBiomarkersC-Reactive Protein

Autor:innen und Institutionen

  • Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), CIBERCV, Universitat Autònoma de Barcelona, Carrer de Sant Quintí, 89, Barcelona 08025, Spain.
  • Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.
  • Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

ORCID-Profile: Guiomar Mendieta, Gianluigi Pironti, Jasper Tromp

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Mendieta, G., Pironti, G., Tromp, J., & Lund, L. H. (2026). Inflammatory cytokines and immune signalling in heart failure: mechanisms, models, and emerging therapies. Cardiovascular Research, 122(14), 1901-1921. https://doi.org/10.1093/cvr/cvag172

Vancouver

Mendieta G, Pironti G, Tromp J, Lund LH. Inflammatory cytokines and immune signalling in heart failure: mechanisms, models, and emerging therapies. Cardiovascular Research. 2026;122(14):1901-1921. doi:10.1093/cvr/cvag172

BibTeX
@article{Mendieta2026,
  author = {Mendieta, Guiomar and Pironti, Gianluigi and Tromp, Jasper and Lund, Lars H},
  title = {Inflammatory cytokines and immune signalling in heart failure: mechanisms, models, and emerging therapies},
  journal = {Cardiovascular Research},
  year = {2026},
  volume = {122},
  number = {14},
  pages = {1901--1921},
  doi = {10.1093/cvr/cvag172}
}
Kostenlos starten →